Direct
NAV (17-Jun-25)
Returns (Since Inception)
Fund Size
₹2,961 Cr
Expense Ratio
0.62%
ISIN
INF740KA1LG1
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
30 Nov 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+16.03%
+14.51% (Cat Avg.)
3 Years
+28.47%
+25.57% (Cat Avg.)
5 Years
+24.72%
+21.51% (Cat Avg.)
Since Inception
+24.57%
— (Cat Avg.)
Equity | ₹2,948.97 Cr | 99.58% |
Others | ₹12.39 Cr | 0.42% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Cipla Ltd | Equity | ₹262.43 Cr | 8.86% |
Cohance Lifesciences Ltd | Equity | ₹260.83 Cr | 8.81% |
Sun Pharmaceuticals Industries Ltd | Equity | ₹257.61 Cr | 8.70% |
Ipca Laboratories Ltd | Equity | ₹241.7 Cr | 8.16% |
Gland Pharma Ltd | Equity | ₹146.26 Cr | 4.94% |
Alembic Pharmaceuticals Ltd | Equity | ₹145.4 Cr | 4.91% |
Globus Medical Inc Class A | Equity | ₹135.97 Cr | 4.59% |
Laurus Labs Ltd | Equity | ₹135.2 Cr | 4.57% |
Apollo Hospitals Enterprise Ltd | Equity | ₹134.01 Cr | 4.53% |
Sai Life Sciences Ltd | Equity | ₹120.89 Cr | 4.08% |
Illumina Inc | Equity | ₹112.76 Cr | 3.81% |
Pfizer Ltd | Equity | ₹112.63 Cr | 3.80% |
Kovai Medical Center & Hospital Ltd | Equity | ₹102.12 Cr | 3.45% |
Procter & Gamble Health Ltd | Equity | ₹91.22 Cr | 3.08% |
Vijaya Diagnostic Centre Ltd | Equity | ₹89.46 Cr | 3.02% |
Intuitive Surgical Inc | Equity | ₹88.61 Cr | 2.99% |
Concord Biotech Ltd | Equity | ₹85.64 Cr | 2.89% |
Indoco Remedies Ltd | Equity | ₹81.06 Cr | 2.74% |
Unichem Laboratories Ltd | Equity | ₹50.97 Cr | 1.72% |
Emcure Pharmaceuticals Ltd | Equity | ₹45.59 Cr | 1.54% |
ICICI Lombard General Insurance Co Ltd | Equity | ₹45.27 Cr | 1.53% |
Aarti Drugs Ltd | Equity | ₹37.82 Cr | 1.28% |
Abbott Laboratories | Equity | ₹36.08 Cr | 1.22% |
Narayana Hrudayalaya Ltd | Equity | ₹24.15 Cr | 0.82% |
Thyrocare Technologies Ltd | Equity | ₹24.03 Cr | 0.81% |
Alkem Laboratories Ltd | Equity | ₹19.03 Cr | 0.64% |
Medplus Health Services Ltd | Equity | ₹18.56 Cr | 0.63% |
Treps / Reverse Repo Investments | Cash - Repurchase Agreement | ₹17.84 Cr | 0.60% |
Global X Genomics & Biotechnology ETF | Mutual Fund - ETF | ₹16.27 Cr | 0.55% |
Jupiter Life Line Hospitals Ltd | Equity | ₹13.79 Cr | 0.47% |
Laxmi Dental Ltd | Equity | ₹10.76 Cr | 0.36% |
Net Receivables/Payables | Cash | ₹-5.47 Cr | 0.18% |
GRAIL Inc | Equity | ₹2.87 Cr | 0.10% |
Large Cap Stocks
17.56%
Mid Cap Stocks
14.86%
Small Cap Stocks
53.54%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹2,887.44 Cr | 97.50% |
Financial Services | ₹45.27 Cr | 1.53% |
Standard Deviation
This fund
15.15%
Cat. avg.
16.03%
Lower the better
Sharpe Ratio
This fund
1.13
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
Since December 2020
ISIN | INF740KA1LG1 | Expense Ratio | 0.62% | Exit Load | No Charges | Fund Size | ₹2,961 Cr | Age | 6 years 6 months | Lumpsum Minimum | ₹100 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹321.02 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹321.02 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹108.88 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹108.88 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹331.66 Cr | 24.2% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹331.66 Cr | 26.4% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹10.25 Cr | 12.4% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹434.55 Cr | 13.7% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹434.55 Cr | 11.8% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹1704.87 Cr | 24.6% |
Total AUM
₹1,88,100 Cr
Address
West Wing, 11th Floor, Mumbai, 400021
Your principal amount will be at Very High Risk